216 related articles for article (PubMed ID: 21923736)
81. Clinical review of glimepiride.
McCall AL
Expert Opin Pharmacother; 2001 Apr; 2(4):699-713. PubMed ID: 11336617
[TBL] [Abstract][Full Text] [Related]
82. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited.
Cleveland JC; Meldrum DR; Cain BS; Banerjee A; Harken AH
Circulation; 1997 Jul; 96(1):29-32. PubMed ID: 9236412
[TBL] [Abstract][Full Text] [Related]
83. Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl-carbamoyl]-benzoic acid ([11C]methoxy-repaglinide): a potential beta-cell imaging agent.
Wängler B; Beck C; Shiue CY; Schneider S; Schwanstecher C; Schwanstecher M; Feilen PJ; Alavi A; Rösch F; Schirrmacher R
Bioorg Med Chem Lett; 2004 Oct; 14(20):5205-9. PubMed ID: 15380228
[TBL] [Abstract][Full Text] [Related]
84. Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials.
Mannucci E; Monami M; Candido R; Pintaudi B; Targher G;
Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1601-1608. PubMed ID: 32811736
[TBL] [Abstract][Full Text] [Related]
85. Nicotinamide-rich diet protects the heart against ischaemia-reperfusion in mice: a crucial role for cardiac SUR2A.
Sukhodub A; Du Q; Jovanović S; Jovanović A
Pharmacol Res; 2010 Jun; 61(6):564-70. PubMed ID: 20083200
[TBL] [Abstract][Full Text] [Related]
86. Does inhibiting Sur1 complement rt-PA in cerebral ischemia?
Simard JM; Geng Z; Silver FL; Sheth KN; Kimberly WT; Stern BJ; Colucci M; Gerzanich V
Ann N Y Acad Sci; 2012 Sep; 1268():95-107. PubMed ID: 22994227
[TBL] [Abstract][Full Text] [Related]
87. Gliclazide modified release: from once-daily administration to 24-hour blood glucose control.
Harrower A
Metabolism; 2000 Oct; 49(10 Suppl 2):7-11. PubMed ID: 11078469
[TBL] [Abstract][Full Text] [Related]
88. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?
Meier JJ; Gallwitz B; Schmidt WE; Mügge A; Nauck MA
Heart; 2004 Jan; 90(1):9-12. PubMed ID: 14676228
[TBL] [Abstract][Full Text] [Related]
89. Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas.
Kunte H; Busch MA; Trostdorf K; Vollnberg B; Harms L; Mehta RI; Castellani RJ; Mandava P; Kent TA; Simard JM
Ann Neurol; 2012 Nov; 72(5):799-806. PubMed ID: 23280795
[TBL] [Abstract][Full Text] [Related]
90. Absence of exacerbation of myocardial stunning in anesthetized dogs treated with KAD-1229, a novel hypoglycemic agent.
Ichikawa K; Maruyama K; Murakami M; Tsuji A; Yamato T; Kusama H; Kojima M
Eur J Pharmacol; 2001 Nov; 431(3):331-8. PubMed ID: 11730726
[TBL] [Abstract][Full Text] [Related]
91. Sulfonylurea receptor 1 in central nervous system injury: a focused review.
Simard JM; Woo SK; Schwartzbauer GT; Gerzanich V
J Cereb Blood Flow Metab; 2012 Sep; 32(9):1699-717. PubMed ID: 22714048
[TBL] [Abstract][Full Text] [Related]
92. [Differences between oral antidiabetics].
Bleskestad IH; Birkeland KI
Tidsskr Nor Laegeforen; 2003 Mar; 123(6):808-9. PubMed ID: 12693123
[No Abstract] [Full Text] [Related]
93. Conformational analysis of non-sulfonylurea hypoglycemic agents of the meglitinide family.
Lins L; Brasseur R; Malaisse WJ
Biochem Pharmacol; 1995 Nov; 50(11):1879-84. PubMed ID: 8615868
[TBL] [Abstract][Full Text] [Related]
94. [Pharmacological and clinical profile of mitiglinide calcium hydrate (Glufast), a new insulinotropic agent with rapid onset].
Ojima K; Kiyono Y; Kojima M
Nihon Yakurigaku Zasshi; 2004 Oct; 124(4):245-55. PubMed ID: 15467258
[TBL] [Abstract][Full Text] [Related]
95. Glinide, but not sulfonylurea, can evoke insulin exocytosis by repetitive stimulation: imaging analysis of insulin exocytosis by secretagogue-induced repetitive stimulations.
Aoyagi K; Ohara-Imaizumi M; Nishiwaki C; Nakamichi Y; Nagamatsu S
Exp Diabetes Res; 2009; 2009():278762. PubMed ID: 20069052
[TBL] [Abstract][Full Text] [Related]
96. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin.
Gangji AS; Cukierman T; Gerstein HC; Goldsmith CH; Clase CM
Diabetes Care; 2007 Feb; 30(2):389-94. PubMed ID: 17259518
[TBL] [Abstract][Full Text] [Related]
97. Photohemolytic potency of oral antidiabetic drugs in vitro: effects of antioxidants and a nitrogen atmosphere.
Selvaag E
Photodermatol Photoimmunol Photomed; 1996 Aug; 12(4):166-70. PubMed ID: 9017793
[TBL] [Abstract][Full Text] [Related]
98. Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients.
Schotborgh CE; Wilde AA
Cardiovasc Res; 1997 Apr; 34(1):73-80. PubMed ID: 9217875
[TBL] [Abstract][Full Text] [Related]
99. [Non-SU, insulin secretagogues].
Kikuchi M
Nihon Rinsho; 1999 Mar; 57(3):702-8. PubMed ID: 10199157
[TBL] [Abstract][Full Text] [Related]
100. Sulfonylurea receptor as a target for molecular imaging of pancreas beta cells with (99m)Tc-DTPA-glipizide.
Oh CS; Kohanim S; Kong FL; Song HC; Huynh N; Mendez R; Chanda M; Edmund Kim E; Yang DJ
Ann Nucl Med; 2012 Apr; 26(3):253-61. PubMed ID: 22237676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
